Aging and Drug Therapy

  • G. Barbagallo-Sangiorgi
  • A. N. Exton-Smith

Part of the Ettore Majorana International Science Series book series (PSLI)

Table of contents

  1. Front Matter
    Pages i-x
  2. I. H. Stevenson
    Pages 1-8
  3. S. Garattini, A. de Blasi
    Pages 9-22
  4. S. M. Chierichetti
    Pages 23-30
  5. M. J. Denham
    Pages 51-62
  6. Peter J. Cook
    Pages 63-82
  7. R. M. Fraser
    Pages 95-103
  8. A. Agnoli, N. Martucci, V. Manna
    Pages 105-120
  9. L. Bracco, D. Insitari, L. Amaducci
    Pages 121-127
  10. I. Simeone
    Pages 139-148
  11. Peter H. Millard, Eleanor Peel, Sue Thomas
    Pages 149-153
  12. F. S. Feruglio
    Pages 175-187
  13. A. Ventura, U. Senin, E. Mannarino
    Pages 189-193
  14. R. Fellin, G. Valerio, T. Beroldin, A. L. Angelini, O. De Candia, G. Crepaldi
    Pages 195-220
  15. M. Passeri, E. Palummeri
    Pages 231-252
  16. A. Caniggia
    Pages 253-260
  17. F. I. Caird
    Pages 271-273
  18. N. G. Dey, C. M. Castleden, J. E. F. Pohl
    Pages 275-282
  19. P. U. Carbonin, M. Di Gennaro, R. Bernabei, A. Cocchi, L. Carosella, M. Pahor et al.
    Pages 283-310
  20. G. Barbagallo Sangicrgi, A. Di Sciacca, G. Frada Jr., F. Durante, G. Costanza, G. Cupidi
    Pages 311-325
  21. Fabrizio Fabris
    Pages 327-336
  22. John L. C. Dall
    Pages 337-343
  23. William Davison
    Pages 345-355
  24. F. Rengo, D. Bonaduce, N. Ferrara, V. Canonico, M. Petretta, P. Abete et al.
    Pages 357-375
  25. N. Marchionni, R. Pini, A. Vannucci, M. Calamandrei, A. Conti, M. di Bari et al.
    Pages 377-402
  26. M. Impallomeni
    Pages 403-411
  27. P. W. Overstall
    Pages 413-418
  28. J. Malone-Lee
    Pages 419-440
  29. R. Schmutzler
    Pages 461-477
  30. M. R. P. Hall
    Pages 479-486
  31. S. Govoni, G. Pasinetti, C. Missale, P. F. Spano, M. Trabucchi
    Pages 487-493
  32. G. P. Vecchi, M. Neri, R. Lugli, L. A. Pini, L. Calza
    Pages 507-518
  33. Back Matter
    Pages 519-523

About this book


One of the greatest advances in Geriatric Medicine during the last quarter of a century has been the increased realization of the possibilities of treatment for elderly patients. Neglect has been replaced by a more optimistic therapeutic endeavour and countless old people have benefitted from this approach. But there is also a drawback, and this is the risk of hazardous side effects of medication which are often directly proportional to the biological potency of the drug and may be unpredictably increased due to changes in the senile organism. In fact the anatomical and biological changes in old age alter both the kinetics of most drugs and the receptor response. On account of these changes the individual tolerance of aged patients to drug therapy may be quite different from that of younger subjects. Thus for a variety of reasons elderly patients receive more drugs, but they are at a higher risk of encountering adverse reactions, which often show atypical clinical features. We can therefore speak of "geriatric iatrogenic disorders" and point out that some of these side effects are determined by a complex pathogenesis due to the particular pathophysiological condition in the elderly. It is important to encourage the habit of individ­ ually evaluating potential risk versus expected advantages of drugs in keeping with the same principles adopted in the evaluation of cost/benefit ratio.


Potential aging brain clinical trial geriatrics pain pathogenesis pathology pharmacology rehabilitation

Editors and affiliations

  • G. Barbagallo-Sangiorgi
    • 1
  • A. N. Exton-Smith
    • 2
  1. 1.Institute of Internal Medicine and GeriatricsUniversity of PalermoPalermoItaly
  2. 2.School of MedicineUniversity College LondonLondonEngland

Bibliographic information

Industry Sectors
Materials & Steel
Chemical Manufacturing
Consumer Packaged Goods
Energy, Utilities & Environment